title: Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes.
abstract: Fatty acids are an important ligand for peroxisome proliferator-activated receptor (PPAR) activation and transcriptional regulation of metabolic genes. To examine whether reduced plasma free fatty acid (FFA) availability affects the mRNA content of proteins involved in fuel metabolism in vivo, the skeletal muscle mRNA content of various transcription factors, transcriptional coactivators and genes encoding for lipid regulatory proteins were examined before and after 3 h of cycle exercise with (NA) and without (CON) pre-exercise ingestion of nicotinic acid (NA). NA resulted in a marked (3- to 6-fold) increase (P<0.05) in PPARalpha, PPARdelta and PPAR coactivator 1alpha (PGC1alpha) mRNA, but was without effect on nuclear respiratory factor-1 and Forkhead transcription factor, fatty acid transcolase/CD36, carnitine palmitoyl transferase 1, hormone sensitive lipase (HSL) and pyruvate dehydrogenase kinase 4. Exercise in CON was associated with increased (P<0.05) PPARalpha, PPARdelta and PGC1alpha mRNA, which was similar in magnitude to levels observed with NA at rest. Exercise was generally without effect on the mRNA content of lipid regulatory proteins in CON and did not affect the mRNA content of the measured subset of transcription factors, transcriptional co-activators and lipid regulatory proteins during NA. To determine the possible mechanisms by which NA might affect PGC1alpha expression, we measured p38 MAP kinase (MAPK) and plasma epinephrine. Phosphorylation of p38 MAPK was increased (P<0.05) by NA treatment at rest, and this correlated (r2=0.84, P<0.01) with increased PGC1alpha. Despite this close relationship, increasing p38 MAPK in human primary myotubes was without effect on PGC1alpha mRNA content. Plasma epinephrine was elevated (P<0.05) by NA at rest (CON: 0.27+/-0.06, NA: 0.72+/-0.11 nM) and throughout exercise. Incubating human primary myotubes with epinephrine increased PGC1alpha independently of changes in p38 MAPK phosphorylation. Hence, despite the fact that NA ingestion decreased FFA availability, it promoted the induction of PPARalpha/delta and PGC1alpha gene expression to a similar degree as prolonged exercise. We suggest that the increase in PGC1alpha may be due to the elevated plasma epinephrine levels. Despite these changes in transcription factors/coactivators, the mRNA content of lipid regulatory proteins was generally unaffected by plasma FFA availability.
authors.affiliation: Skeletal Muscle Research Laboratory, School of Medical Sciences, Royal Melbourne Institute of Technology, PO Box 27, Bundoora 3083, Victoria, Australia. matthew.watt@rmit.edu.au
authors.forename: M J
authors.initials: MJ
authors.lastname: Watt
authors.forename: R J
authors.initials: RJ
authors.lastname: Southgate
authors.forename: A G
authors.initials: AG
authors.lastname: Holmes
authors.forename: M A
authors.initials: MA
authors.lastname: Febbraio
mesh_terms: D018955:CD36 Antigens / Q000187:drug effects / Q000235:genetics; D000001:Calcimycin / Q000494:pharmacology; D002334:Carnitine O-Palmitoyltransferase / Q000187:drug effects / Q000235:genetics; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004837:Epinephrine / Q000097:blood; D005080:Exercise Test; D005227:Fatty Acids / Q000097:blood*; D051858:Forkhead Transcription Factors; D006360:Heat-Shock Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology; D008055:Lipids / Q000235:genetics; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009525:Niacin / Q000494:pharmacology*; D009687:Nuclear Proteins / Q000187:drug effects / Q000235:genetics; D047493:PPAR alpha / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D047494:PPAR delta / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; D010766:Phosphorylation; D011494:Protein Kinases / Q000187:drug effects / Q000235:genetics; D011725:Pyridines / Q000494:pharmacology; D002787:Sterol Esterase / Q000187:drug effects / Q000235:genetics; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D015854:Up-Regulation; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D018955:CD36 Antigens; D004791:Enzyme Inhibitors; D005227:Fatty Acids; D051858:Forkhead Transcription Factors; D006360:Heat-Shock Proteins; D000960:Hypolipidemic Agents; D007093:Imidazoles; D008055:Lipids; D009687:Nuclear Proteins; D047493:PPAR alpha; D047494:PPAR delta; C486497:PPARGC1A protein, human; D000071248:Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; D011725:Pyridines; D014157:Transcription Factors; D009525:Niacin; D000001:Calcimycin; D002334:Carnitine O-Palmitoyltransferase; D011494:Protein Kinases; C403287:pyruvate dehydrogenase kinase 4; D048051:p38 Mitogen-Activated Protein Kinases; D002787:Sterol Esterase; C093642:SB 203580; D004837:Epinephrine